Business context and reporting period
Filing identity does not match the request: the supplied filing is Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), not Sonoma Pharmaceuticals, Inc. It is a Form 10-K for the fiscal year ended March 31, 2015—not a standalone 2014 Q4 report. The filing provides annual comparisons, not clear standalone fourth-quarter results.
Oculus develops and sells Microcyn-based medical-device products for dermatology and advanced tissue care, alongside animal-health products and laboratory testing services. Management described a strategic shift toward dermatology and building direct U.S. sales capabilities. The financial statements received an unqualified audit opinion, but the auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
Financial performance and liquidity
| Metric | FY ended Mar. 31, 2015 | FY ended Mar. 31, 2014 |
|---|---|---|
| Total revenue | $13.854 million | $13.668 million |
| Gross profit | $7.288 million | $8.397 million |
| Operating loss | $6.659 million | $6.051 million |
| Net income (loss) | $(8.203) million | $3.735 million |
| Net income (loss) per share, diluted | $(0.85) | $0.54 |
| Net cash used in operations | $6.694 million | $4.890 million |
| Cash and cash equivalents at year-end | $6.136 million | $5.480 million |
- Consolidated gross margin was approximately 52.6%, down from approximately 61.4%. Management separately reported product gross margin of 55%, versus 65%; the filing attributes the product-margin decline chiefly to lower Innovacyn royalties.
- Revenue mix in FY2015: product sales $9.939 million; product licensing fees and royalties $3.056 million; services $859,000. Product sales rose 38% in the United States, 34% in Mexico, and 42% in Europe and the rest of the world. Licensing and royalty revenue fell 45%.
- Operating expenses were $13.947 million, including $12.414 million of selling, general and administrative expense and $1.533 million of research and development expense. R&D fell 47%, partly because the prior year included Ruthigen costs; SG&A increased 7% as the company expanded dermatology sales and launched products.
- FY2015 net loss included a $4.650 million impairment of the Ruthigen investment and a $3.164 million noncash gain from revaluing derivative liabilities. FY2014 included an $11.133 million gain on Ruthigen’s deconsolidation, materially affecting the year-over-year net-income comparison.
- Working capital was $7.066 million, versus $1.970 million a year earlier. Total assets were $15.048 million and total liabilities $2.994 million at March 31, 2015. Reported debt was $87,000, all current; the company said its prior venture-lender debt had been settled in full by March 2014.
- Operating cash burn exceeded cash raised through financing in FY2015; net cash increased $656,000, with financing cash inflows of $6.609 million and investing cash inflows of $875,000. Approximate operating cash flow less property-and-equipment purchases was negative $6.833 million.
Material changes, outlook, and risks
- Revenue and customer changes: Innovacyn’s animal-health business contributed $1.120 million, or 8% of FY2015 revenue, compared with $3.100 million, or 23%, in FY2014. Oculus terminated the arrangements in December 2014 and appointed SLA Brands as a new distributor; management warned replacement revenue was uncertain. More Pharma, responsible with Laboratorios Sanfer for 47% of FY2015 revenue, was acquired by Sanfer. Sanfer represented 56% of year-end net receivables; Dyamed represented another 14%.
- Capital and going concern: Management expects continued losses and says additional capital may be needed to fund commercialization and operations. It had no committed new financing and warned that failure to raise capital could require cost reductions and delay commercialization. The going-concern uncertainty is not reflected through adjustments to the audited statements.
- Outlook: Management expected R&D expense to remain relatively flat over the next year and SG&A to increase over several quarters as it expands direct sales and launches products. It cited planned dermatology launches, including a post-laser product targeted for fall 2015. U.S. drug development and pivotal trials depended on securing a strategic partner or additional capital; no quantified revenue or earnings guidance was provided.
- Ruthigen: The company recorded the $4.650 million investment impairment after agreeing to sell shares at $2.75 each. Sale of its remaining 1.65 million shares for approximately $4.538 million was contingent on the Pulmatrix-Ruthigen merger closing; the filing gives no assurance of completion or receipt of proceeds.
- Listing, dilution, and legal matters: Nasdaq notified Oculus that its share price had been below the $1.00 minimum bid requirement and gave it until September 2, 2015 to regain compliance; the company said a reverse split might be used. The January 2015 offering generated $5.444 million net proceeds but issued substantial shares and warrants. Exeltis alleged breach of a former exclusive distribution agreement concerning Alevicyn gel; Oculus disputed the claim, intended to defend itself, and recorded no loss accrual.
- Other risks: product acceptance, regulatory approvals, reimbursement, international operations and foreign exchange, customer concentration and collections, manufacturing compliance, intellectual-property protection, and competition are material risks. Microcyn had U.S. medical-device clearances, but the company lacked approval to market it as a drug in the United States.
Investor facts to verify
- Confirm the intended issuer and period: this is an Oculus FY2015 10-K, not a Sonoma Pharmaceuticals 2014 Q4 filing.
- Review the going-concern disclosures, cash runway, operating cash burn, and available financing; verify whether subsequent financing was completed and on what terms.
- Track whether the Ruthigen share sale and Pulmatrix-Ruthigen merger closed and whether Oculus received the expected proceeds.
- Assess whether SLA replaced Innovacyn’s lost animal-health revenue and whether customer concentration and receivable exposure declined.
- Check Nasdaq bid-price compliance, subsequent share and warrant issuance, and the resulting dilution.
- Follow the Exeltis dispute and any subsequent developments in regulatory clearances, product launches, and sales growth.